Long-term risk of rosiglitazone on cardiovascular events: a systematic review and meta-analysis.

Long-term risk of rosiglitazone on cardiovascular events: a systematic review and meta-analysis. Endokrynol Pol. 2018 Jun 28;: Authors: Cheng D, Gao H, Li W Abstract Rosiglitazone has been proposed as a treatment strategy for type 2 diabetes mellitus (T2DM), could provide robust glucose-lowering capability with risk of cardiovascular events. We thus did a systematic review and meta-analysis of controlled trials to assess the effect of this treatment on glycaemic control, cardiovascular events in patients with T2DM. We systematically search PubMed, Embase and Cochrane Central Register of Controlled Trials comparing rosiglitazone to other anti-diabetic treatments. These studies included randomized controlled trials (RCTs), cohort studies, and case-control studies that had treatment at least 6 months of follow-up in patients with T2DM. We aimed to evaluate the long-term effect on cardiovascular risk of rosiglitazone compared with basal insulin drug. Main outcomes included myocardial infarction, heart failure, stroke, cardiovascular mortality and all-cause mortality. We included 11RCTs and 4 observational studies involving 20,079 individuals with T2DM allocated to rosiglitazone and a similar number to comparison groups of which only five compared rosiglitazone with placebo and collected data on cardiovascular outcomes. Among patients with T2DM, the rosiglitazone is associated with a significantly increased risk of heart failure, with lit...
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research